Information on the dilution and adulteration of copyright is not really routinely collected in Europe. Nevertheless, according to complementary facts documented on the EMCDDA and data obtainable from other resources, some Examination of new tendencies pertaining to pharmacologically active adulterants in copyright products in Europe is often carrie